New diagnostic and therapeutic tools combining nanotechnology have been developed in recent medical research, which are beneficial to the specific transport and absorption of drugs and contrast agents to the brain, as well as promoting the regeneration of damaged neurons to limit or reverse neurological disorders. As a common neurological condition, dementia affected 46.8 million individuals globally in 2015, with that figure expected to rise to 131.5 million by 2050. Early identification is critical for efficient treatment of AD since neuro invasiveness and degenerative changes begin before the onset of symptoms. To detect and identify amyloid plaques, most investigations use magnetic resonance imaging (MRI) using contrast-doped NPs or tagging NPs with fluorescent probes. To combat neurodegenerative disorders, nanotechnology can be applied into neuroscience.
Important Alert:
X
Title : Down’s syndrome (trisomy 21) and alzheimer disease: A common medical and scientific fight
London Jacqueline, Paris Diderot University, France
Title : Memory should be the primary endpoint in early AD
Matthias W Riepe, Ulm University, Germany
Title : Quality of life children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Electrophysiology and alzheimer's pathology: A scoping review on eeg correlations with CSF biomarkers
Charikleia Karastamati, University of Pavia, Italy
Title : The vital role of care homes in supporting individuals with neurological conditions
Akankunda Veronicah, Golden Age Elderly Homes Kampala, Uganda
Title : Semantic-based memory-encoding strategy in enhancing cognitive function and daily task performance for older adults with mild cognitive impairment: A pilot non-randomised
Karen P Y Liu, Western Sydney University, Hong Kong